1-(2,4-Xylyl)piperazine → [4-(2,4-Dimethylphenyl)piperazin-1-yl][4-(imidazo[4,5-b]pyridin-3-yl)phenyl]methanone
반응식
[N:1]1[C:9]2[C:4](=[N:5][CH:6]=[CH:7][CH:8]=2)[N:3]([C:10]2[CH:20]=[CH:19][C:13]([C:14]([O:16]CC)=O)=[CH:12][CH:11]=2)[CH:2]=1.[CH3:21][C:22]1[CH:27]=[C:26]([CH3:28])[CH:25]=[CH:24][C:23]=1[N:29]1[CH2:34][CH2:33][NH:32][CH2:31][CH2:30]1>>[CH3:21][C:22]1[CH:27]=[C:26]([CH3:28])[CH:25]=[CH:24][C:23]=1[N:29]1[CH2:30][CH2:31][N:32]([C:14]([C:13]2[CH:12]=[CH:11][C:10]([N:3]3[C:4]4=[N:5][CH:6]=[CH:7][CH:8]=[C:9]4[N:1]=[CH:2]3)=[CH:20][CH:19]=2)=[O:16])[CH2:33][CH2:34]1참가 물질
3
실험 절차
Using ethyl 4-(imidazo[4,5-b]pyridin-3-yl)benzoate (300 mg) described in Preparation Example 77 and 1-(2,4-dimethylphenyl)piperazine (214 mg) and by the reaction and treatment in the same manner as in Example 109, the title compound (338 mg) was obtained.
출처 및 근거
- ORD 기록
- ord-702b53c55fd64f768e3a2322875ff712
- 출처 데이터셋
- uspto-grants-2014_08